… The disappointing outcomes of DLBCL patients experiencing early rituximab failure (ERF)
in this … therapies and relapsing >12 months after initial diagnosis (late rituximab failure [LRF]). …

… most likely to fail CAR T-cell therapy because of early relapse. … , early progression, and
death after CAR T-cell therapy in patients with R/R DLBCL. Our risk model identifying early failure …

… In our experience, outcomes for patients showing very early failure are even worse (median
PFS-2 was 1.7 months, 95% CI 1.1-2.4). These results mirror those that occur with …

… This study aimed to evaluate the failure patterns and clinical implications in patients with
early stage nasal natural killer (NK)/T-cell lymphoma treated with primary radiotherapy. …

… that early FDG-PET response using Deauville criteria may predict the risk of CAR-T failure
and be used to guide post–CAR-T management. Although patients achieving early DS1 to 2 …

… Diffuse large B-cell lymphoma (DLBCL) is the most common … late treatment failure (n = 28),
those who had early treatment failure (… who had late failure, those who had early failure had a …

… -free survival (PFS) and overall survival (OS) in DLBCL patients, this difference being
more relevant in germinal center B-cell lymphoma than activated B-cell lymphoma subtypes. …

… We also identified lymphomas harboring MYC translocation, hereafter designated MYC(+), …
at initial diagnosis and at time of treatment failure,20 we utilized FISH information from initial …

… In order to better understand the reasons associated with CAR-T cell therapy failures, we
need to take a deep look into the available information in clinical trials and retrospective …

… The International Atomic Energy Agency sponsored a large, multinational, prospective
study to further define PET for risk stratification of diffuse large B-cell lymphoma and to test the …